COVID-19 in patients with IBD and pancreaticobiliary disorders

Posted August 21, 2020

■ ABSTRACT

Evidence shows that COVID-19 can exacerbate symptoms of inflammatory bowel disease (IBD) and pancreaticobiliary disorders, and it is important to distinguish between an IBD exacerbation and symptoms caused by COVID-19. Although IBD does not appear to increase the risk for COVID-19 or worsen outcomes, corticosteroids can increase the risk and should be avoided when treating these patients. Pancreatic and biliary disease have been described in patients with COVID-19, but it is not clear whether COVID-19 induces these diseases. For facilities resuming endoscopic procedures, there are consensus guidelines for minimizing the COVID-19 transmission risks with these procedures.

■ IBD AND COVID-19

One-third of patients with COVID-19 present with gastrointestinal (GI) symptoms.1 Patients with inflammatory bowel disease (IBD) often present with GI symptoms as part of their disease. Practitioners should consider COVID-19 in patients with IBD who experience disease exacerbation, especially if the symptoms are not typical for their disease flare.

A US cohort study found that IBD patients with COVID-19 more frequently presented with diarrhea and abdominal pain than non-IBD matched controls.2 In addition, the study found that IBD patients with COVID-19 had higher rates of new onset diarrhea, abdominal pain, endoscopically active disease, and elevated biomarkers as opposed to IBD patients without COVID-19, suggesting that COVID-19 may present as an IBD flare in these patients.2 It is important to note that fecal calprotectin also may be elevated in patients with COVID-19–associated diarrhea and, therefore, may not help discern complications of infection from IBD activity.3 A careful clinical assessment, in addition to COVID-19 testing and endoscopic evaluation, are sometimes necessary to distinguish between an IBD exacerbation and symptoms caused by COVID-19.

Risk of SARS-CoV-2 infection in IBD

Patients with IBD do not appear to be at increased risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a study from New York City (NYC), patients with IBD were found to have similar rates of infection as the general population.2 However, corticosteroid use and moderate to severe disease activity were associated with higher rates of infection in these patients. Conversely, SARS-CoV-2 infection rates did not differ across biologic treatment classes. Similarly, in a large nationwide Veterans Administration cohort, thiopurines or antitumor necrosis factor (anti-TNF) agents were not associated with an increased risk of SARS-CoV-2 infection in IBD.4

Studies from Asia and Europe have corroborated this finding, reporting COVID-19 rates that were not increased in IBD patients.5–7 In a Spanish study, patients with IBD were found to have a lower adjusted incidence ratio of COVID-19 (odds ratio 0.74, 95% confidence interval 0.70–0.77, P <.001) compared with the general population.6 In our experience, patients with IBD typically practice careful hand hygiene and social distancing, which may be part of the reason for decreased prevalence of COVID-19 in these patients.

Risk of severe COVID-19 with IBD

Patients with IBD do not appear to have worse outcomes with COVID-19.6,8,9 A report from a NYC hospital system noted that the hospitalization rate among immunosuppressed patients with IBD and
other autoimmune conditions was similar to the overall NYC population.\(^9\) In addition, the NYC case-control study found that patients with IBD and COVID-19 had outcomes similar to patients without IBD.\(^2\) Furthermore, biologic use did not increase the risk of severe COVID-19. Other studies have shown similar findings. In a Spanish study, patients with IBD were found to have mortality rates comparable with the average population.\(^6\)

Early in the pandemic, the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry was established to collect data on the impact of COVID-19 in patients with IBD. As of August 11, 2020, 2,035 cases of IBD and COVID-19 had been reported in 56 countries.\(^10\) A multivariable analysis by Brenner et al of the first 525 cases found that anti-TNF therapy was not associated with worse COVID-19 outcomes,\(^8\) which is consistent with other studies.\(^2,9\) Risk factors associated with severe COVID-19 were increased age, the presence of 2 or more comorbidities, corticosteroid use, and 5-aminosalicylate use.\(^6\) In addition, active IBD was associated with an increased risk of hospitalization and mortality in an Italian prospective cohort of IBD patients and COVID-19.\(^11\)

High-dose corticosteroid therapy (eg, prednisone > 20 mg/day) was also identified as a risk factor for worse COVID-19 outcomes in the cohort of NYC patients with IBD and other autoimmune conditions.\(^9\) Further, corticosteroid use has been associated with negative outcomes in the treatment of other coronaviruses, including severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV).\(^12\) However, it is important to note that a recent trial found a survival benefit with the administration of a short course of dexamethasone in critically ill patients with COVID-19.\(^13\) This paradox is likely explained by the fact that patients actively taking prednisone at the time of the viral infection had worsening infection and mortality, whereas steroids given in response to the cytokine storm likely improves the immune-mediated systemic inflammatory reaction.

Surprisingly, aminosalicylates were found to be associated with more severe COVID-19, even after adjusting for possible confounders.\(^14\) The clinical implications of this cannot be fully understood until further study to detect unmeasured confounders or underlying mechanistic properties.

### Management of IBD and COVID-19

Efforts to provide guidance for IBD management began early in the COVID-19 pandemic and have been adjusted as evidence accumulates. Several expert groups have published consensus guidelines on this disease state.\(^15-18\) It is important to note that these recommendations are largely based on expert opinion and consensus, given the limited data.

Among their recommendations are to keep patients with IBD on therapy but to decrease or stop corticosteroids, if possible. If a patient develops COVID-19, immunosuppressive therapy should be held in most instances. Recent evidence has not shown worse outcomes with biologics. In fact, certain agents such as anti-TNFs and Janus kinase (JAK) inhibitors are being evaluated as potential COVID-19 therapies. The management of patients with IBD should be individualized according to their disease activity and severity of COVID-19 infection.

Based on updated guidelines from the International Organization for the Study of Inflammatory Bowel Disease (IOIBD), if immunosuppressive therapies are held because of COVID-19, they may be restarted at least 10 days after COVID-19 symptom onset and at least 3 days since recovery.\(^18\) Having 2 consecutive negative PCR tests is no longer required. However, evidence is still lacking regarding the timing and safety of resuming therapy after COVID-19, and this deserves further investigation. Recommendations for the management of IBD patients with COVID-19 based on disease severity are summarized in Table 1.

### Summary for IBD

Patients with IBD do not appear to be at increased risk of developing COVID-19; however, corticosteroid use and moderate to severe disease activity are associated with higher rates of SARS-CoV-2 infection. In addition, although IBD patients with COVID-19 have similar outcomes as the general population, several risk factors are associated with more severe COVID-19 in these patients, including corticosteroid use, older age, comorbidities, and active disease. Patients, therefore, should remain on therapy to maintain remission while continuing to avoid corticosteroids.

#### PANCREATICOBILIARY DISEASE AND COVID-19

The SARS-CoV-2 uses the angiotensin-converting enzyme-2 (ACE-2) to enter host cells.\(^19\) The ACE-2 is expressed in the GI tract as well as in pancreatic cells and cholangiocytes. Although pancreatic and
Biliary disease have been described in patients with COVID-19, the exact role of SARS-CoV-2 in this context remains to be determined.

Pancreatic manifestations
Elevated pancreatic enzymes have been described in association with COVID-19. A US multicenter retrospective study found increased lipase levels in 12.1% of patients (9 of 71), with 2.8% having elevations greater than 3 times the upper limit of normal. In a study from China, 17% of patients (9 of 52) with COVID-19 had an abnormal lipase or amylase level. Although clinical pancreatitis is rare, cases of acute pancreatitis in patients with COVID-19 have been described. In addition, SARS-CoV-2 RNA has been detected in a pseudocyst fluid sample in a COVID-19 patient with prior idiopathic pancreatitis.

Whether COVID-19 induces pancreatic disease is unclear. Although a direct cytopathic effect is plausible and has been suggested, other usual causes of pancreatitis should still be considered, in addition to possible pancreatic injury associated with multiorgan dysfunction or hypoperfusion with COVID-19.

Biliary manifestations
SARS-CoV-2 RNA has been detected in the bile of a patient with biliary obstruction in a transplanted liver. Interestingly, the viral load in bile was found to be higher than in sputum. Abnormal abdominal imaging is common among patients with COVID-19. In a cohort study of 412 inpatients with COVID-19, up to 54% undergoing ultrasound imaging (mostly for abnormal liver enzymes) were found to have gallbladder distention.

### Table 1
Treatment of patients with inflammatory bowel disease and COVID-19 (as of July 2020)

<table>
<thead>
<tr>
<th>Severity COVID-19</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Continue 5-ASA, rectal therapies, budesonide</td>
</tr>
<tr>
<td></td>
<td>Hold tofacitinib, methotrexate, and thiopurinesa</td>
</tr>
<tr>
<td></td>
<td>Taper corticosteroids and/or switch to budesonide</td>
</tr>
<tr>
<td></td>
<td>Delay biologics for 2 weeks or until COVID-19 resolvesa</td>
</tr>
<tr>
<td></td>
<td>Individualize each patient: Weigh risks and benefits of COVID and IBD</td>
</tr>
<tr>
<td></td>
<td>treatment. A patient with severe IBD may require treatment irrespective</td>
</tr>
<tr>
<td></td>
<td>of COVID-19</td>
</tr>
<tr>
<td>Moderate</td>
<td>Treat COVID-19 as per local guidelines</td>
</tr>
<tr>
<td></td>
<td>Continue 5-ASA, rectal therapies, budesonide</td>
</tr>
<tr>
<td></td>
<td>Hold tofacitinib, methotrexate, and thiopurinesa</td>
</tr>
<tr>
<td></td>
<td>Taper corticosteroids and/or switch to budesonide</td>
</tr>
<tr>
<td></td>
<td>Delay biologics for 2 weeks or until COVID-19 resolvesa</td>
</tr>
<tr>
<td>Severe</td>
<td>Treat COVID-19 as per local guidelines</td>
</tr>
<tr>
<td></td>
<td>Continue 5-ASA, rectal therapies, budesonide</td>
</tr>
<tr>
<td></td>
<td>Hold tofacitinib, methotrexate and thiopurinesa</td>
</tr>
<tr>
<td></td>
<td>Taper corticosteroids and/or switch to budesonide</td>
</tr>
<tr>
<td></td>
<td>Delay biologics for 2 weeks or until COVID-19 resolvesa</td>
</tr>
</tbody>
</table>

a Considerations for restarting therapy:
- If asymptomatic: wait at least 10 days since date of first positive COVID-19 test.
- If symptomatic: wait at least 10 days since COVID-19 symptom onset and at least 3 days since recovery (defined as resolution of fever and improvement in respiratory symptoms). In severe COVID-19, a longer time frame may be necessary.

AGA = American Gastroenterological Association; ASA = aminosalicylates; IBD = inflammatory bowel disease; IOIBD = International Organization for the Study of Inflammatory Bowel Disease

Adapted from the AGA and IOIBD recommendations.
and sludge. However, the significance of those findings is unclear.

**PERFORMING ENDOSCOPY DURING THE PANDEMIC**

COVID-19 has had a significant impact on the delivery of endoscopy services. Initially, health care facilities postponed nonurgent endoscopic procedures following guidance from national GI societies and state health departments. Procedural volumes were reduced by as much as 80% to 90% in some centers. A US survey showed 65% of endoscopy units were operating at less than 10% of their usual volume, with important procedures such as screening colonoscopies being postponed in 97% of centers. In some institutions, endoscopy units were converted to COVID-19 units and endoscopy staff redeployed to care for COVID-19–positive patients.

While the long-term impact on patient care still needs to be determined, the immediate impact has been substantial. For example, in one US study, patients with GI bleeding were found to have significantly lower odds of undergoing endoscopy compared with patients admitted before the pandemic. In Hong Kong, while procedural volumes were reduced by more than 50%, the number of new GI cancer diagnoses decreased by 49.1%. The impact of COVID-19 on deferred care is substantial and the consequences will likely be realized for years.

**Minimizing transmission risks**

An early report from Spain described a cluster of COVID-19 cases among endoscopy practitioners before protective measures were established. However, a subsequent study from Italy found a low rate of infection among staff and patients in endoscopy units with protective measures.

Given the concerns about the presence of SARS-CoV-2 in the stool and possible transmission of the virus through aerosolization during endoscopic procedures, the American Gastroenterological Association published recommendations for reducing the infection risk. These include the use of N95, N99, or powered air-purifying respirators (PAPR) masks for both upper and lower endoscopies as well as the use of negative-pressure rooms (if available) for COVID-19–positive cases.

Additional evidence on the aerosolization risk during endoscopy procedures has been published. In a prospective trial, esophagogastroduodenoscopy was found to lead to aerosolization of multiple particles of different sizes. Of note, general anesthesia is still associated with aerosolization of all particle sizes, suggesting it does not eliminate the risk of aerosolization during endoscopy. Interestingly, continuous oral suction has been found to decrease the amount of aerosol generated.

**Safely resuming endoscopy**

To help endoscopy units safely resume operations, the American Society for Gastrointestinal Endoscopy has issued recommendations on minimizing infection risks among patients and providers. These recommendations include detailed guidance on preprocedural screening, cleaning, physical distancing, and other periprocedural considerations.

Routine preprocedural testing is not currently recommended, although endoscopy units are encouraged to individualize their approach based on geographical prevalence of COVID-19, as well as the size and type of facility. In a retrospective US study of 396 patients tested before endoscopy, the overall positive rate was 0.25%. The infection rate was significantly lower than in the general population, suggesting preprocedural screening questionnaires may be effective in identifying SARS-CoV-2–positive patients.

**REFERENCES**
